articleThe Lancet OncologySep 10, 2014GREEN OA

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

JFJoyce F. LiuWTWilliam T. BarryMJMichael J. BirrerJMJung Min LeeRJRonald J. Buckanovich

Dana-Farber Cancer Institute · Massachusetts General Hospital · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

583
total citations
FWCI
29.08
Percentile
100%
References
33
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Olaparib
  • Medicine
  • Ovarian cancer
  • Oncology
  • Internal medicine
  • BRCA mutation
  • Clinical endpoint
  • PARP inhibitor
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding